Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin
© BioMed Central Ltd 2007
Published: 26 July 2007
Skip to main content
© BioMed Central Ltd 2007
Published: 26 July 2007
Combination estrogen plus progestin causes breast cancer. In light of this causal relation, the rapid decline in breast cancer incidence noted in 2003, following an earlier and slower reduction in incidence from 1999, raises important issues regarding the proportion of this decline that may be due to a reduction in the use of combination therapy by postmenopausal women. The context of these national trends is reviewed and the strong link to the use of hormone therapy is discussed, after noting that screening cannot explain any substantial component of these trends. The rapid decrease in incidence, most evident among women aged 50 to 69 years and in estrogen receptor positive tumors, that parallels the decline in combination hormone use is consistent with a promoter effect for estrogen plus progestins.
A rigorous analysis of Surveillance, Epidemiology, and End Results (SEER) data , addressing trends on breast cancer incidence, tumor characteristics, and patterns of incidence for in situ cancer, added new insights into the impact that combination hormone therapy has on risk for breast cancer at the population level. Combination therapy (estrogen plus progestin [E&P]) causes breast cancer and is classified as a carcinogen by the International Agency for Research on Cancer . Here, I address how much of the recently reported decrease in incidence  is due to a reduction in the use of combination E&P postmenopausal hormone therapy.
The association of unopposed estrogen with endometrial cancer provides strong evidence that hormone therapy can act as a late promoter of cancer. With the acknowledgment of the causal relation in the 1970s, a sharp decline in estrogen prescribing led to a parallel rapid decrease in incidence of endometrial cancer . Uptake of E&P therapy was somewhat slow, and epidemiologic data in the USA were limited in their ability to separate effects of combination therapy from those of unopposed estrogen. However, by 1995 prospective data indicated that E&P therapy did not protect against breast cancer and that the increase in risk may be greater than for estrogen alone . Although estrogen alone remained the treatment of choice for women without a uterus, between the mid-1970s and the mid-1980s surveillance data showed that the incidence of estrogen receptor positive tumors increased by an average of 131% in the population-based tumor registry of Kaiser Permanente in the USA (Portland, OR) , perhaps implicating the involvement of hormonal factors in the rising incidence of breast cancer.
Population-based epidemiologic studies  and cohort data  matured during the latter 1990s to show that combination E&P therapy significantly increased risk, and that this was most evident among leaner women. Recommendations based on these findings were that women should avoid progestins if possible . A broad range of epidemiologic studies continue to support the causal relation between combination E&P and total breast cancer. Meanwhile, some investigators have focused on the increase in lobular cancer [9, 10]; the clear estrogen receptor positive nature of these lobular tumors, as compared with ductal tumors, which are receptor positive to a lesser extent, provides a clearer indication that this subset of tumors is caused by combination E&P. Studies of receptor positive tumors show that combination therapy clearly increases risk .
In 2002, the Women's Health Initiative (WHI) confirmed the epidemiologic findings relating combination hormone therapy to increased risk for breast cancer. Despite substantial non-adherence to therapy, which exceeded 40% among women randomly assigned to E&P, the predetermined stopping rules for the WHI led the independent data safety monitoring board to stop the trial early because of the adverse effect of therapy on breast cancer . The intention to treat and, more importantly, the adherence-based relative risks (which approximate the relative risks from epidemiologic studies that record use and nonuse of therapy) were consistent with the Heart and Estrogen/Progestin Replacement Study (HERS) trial  and epidemiologic data showing an increase in risk in the initial 2 to 5 years of use. Furthermore, risk increased significantly with duration of therapy.
Based on data from the San Francisco mammography registry, prescribing of E&P peaked in 1999. The use of hormone therapy was increasing at 1% per quarter before publication of the HERS report, but it declined by 1% per quarter after publication . This decline in prescribing continued until the publication of the WHI in 2002, after which a more substantial decline of 18% per quarter was observed. The peak and decline through 1999 to 2002 is concordant with the HERS report in 1998 , which found a significant increase in coronary heart disease during the first year of therapy among women with prevalent coronary disease and, in addition, no long-term benefit in reducing coronary heart disease . The growing epidemiologic evidence published since 2000 on the adverse effects of combination therapy on breast cancer added further support to avoid its use. Considering the prevalence of use of E&P in California, Clarke and coworkers  estimated a population attributable risk (PAR, or the proportion of cases caused by E&P) of up to 11%, based on a prevalence of use of 30% and a relative risk of 1.4. Given that substantially greater relative risks of 2 or higher have been reported , this estimated PAR may be conservative. Assuming a prevalence of use of 17.5% (the average reported for California in 2001 ), a relative risk of 1.49 gives a PAR of 7.9% and a relative risk of 2.0 gives a PAR of 14.9%.
Evidence regarding breast cancer incidence rates now clearly shows a parallel drop in breast cancer consistent with the pattern of decreased prescribing. Jemal and coworkers  conducted a rigorous, state-of-the-art analysis using joint point analysis and drawing on SEER incidence data from 1975 through to 2003. They demonstrated a significant decrease in the incidence of invasive breast cancer from 1999 to 2003 in all 5-year age groups from 45 years and above, and a sharp decrease largely limited to estrogen receptor positive tumors in age groups from 50 to 69 between 2002 and 2003. Furthermore, although others have suggested that a 1% to 3% drop in screening mammography may account for this decline in incidence, Jemal and coworkers provided strong evidence against this contention. If screening were to account for a drop in incidence, then rates of in situ disease would also need to drop because they are almost only detected by mammography. Jemal and coworkers demonstrated that, before screening became widespread, in situ rates were low and rose with the uptake of screening to plateau from 1999 through to 2003. The lack of a drop in in situ cancer offers compelling evidence that a reduction in screening does not account for the drop in incidence of invasive breast cancer.
Others have analyzed SEER data over a shorter period  or draw on the unique resources of the California tumor registry and health maintenance organization datasets  to show similar relations between change in hormone therapy and a decrease in breast cancer incidence. Most recently, Robbins and Clarke  evaluated the change in prescribing, as estimated from the California Health Interview Survey, among almost three million non-Hispanic white women aged 45 to 74 years, and compared the findings with the change in breast cancer incidence across 58 counties in California. This thoughtful analysis shows that, from 2001 to 2004, the incidence of breast cancer declined by 8.8% in the counties with the smallest E&P reductions, by 13.9% in those with intermediate reductions, and by 22.6% in counties with the greatest reductions in combination postmenopausal hormone therapy. Between 2001 and 2003, California Health Interview Survey data did not indicate any significant change in the proportion of women who reported having a mammogram during the previous 2 years, adding further evidence against this as a plausible major explanatory factor for the observed declines in breast cancer incidence. Even more evidence in support of this relation between decrease in E&P prescribing and breast cancer comes from declines in incidence reported in New Zealand  and Germany  that parallel those in the USA.
Trends in obesity in the USA run counter to the decline in breast cancer incidence, the genetic make up of the population has not changed, and there has been a dramatic decline in breast cancer incidence in the USA that is largely confined to estrogen receptor positive tumors, along with similar declines documented in other countries. Given these findings, the evidence unarguably indicates that there is a causal relation between this abrupt reduction in use of E&P hormone therapy and the decline in breast cancer. The public health impact of this must not be underestimated. In fact, this decrease, amounting to approximately 10,000 fewer cases, falls within the range of attributable risk estimates for beast cancer due to E&P, suggesting that these estimates are conservative because not all women have ceased using combination therapy.
Although research issues remain, for instance regarding impact of dose of progestin per month on risk for breast cancer, women should be reassured that these data support a rapid risk reduction following cessation of therapy with E&P. Long-term use may yet cause some residual increase in risk . Finer analysis that accounts for duration of prior use may resolve this issue.
estrogen plus progestin
Heart and Estrogen/Progestin Replacement Study
population attributable risk
Surveillance Epidemiology, and End Results
Women's Health Initiative.